Blood test may spot bone fracture risk better than X-Rays

NCT ID NCT06551155

Recruiting now Diagnosis Sponsor: Istituto Ortopedico Rizzoli Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new blood-based method to diagnose osteoporosis and predict fracture risk. Researchers will analyze the vitality and behavior of certain blood cells from 120 healthy, osteopenic, and osteoporotic adults aged 40 and older. The goal is to see if this approach is more accurate than current bone density scans (DXA) for identifying different stages of bone loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Diagnostic test using peripheral blood mononuclear cells (PBMCs)
What this could lead to: If successful, this could provide a more accurate, blood-based way to diagnose osteoporosis and predict fracture risk, potentially reducing misdiagnosis.
What could go wrong: This is an early-stage diagnostic study with 120 participants, so the test may not prove accurate enough for widespread use. It also requires further validation before becoming a standard tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic disease osteoporosis Osteoporotic Fractures

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPENIA OSTEOPOROSIS OSTEOPOROSIS FRACTURE

Contacts and locations

Locations

Azienda Ospedaliero Universitaria Policlinico G.Rodolico - San Marco
RECRUITING

Catania, 95123, Italy
Istituto Ortopedico Rizzoli
RECRUITING

Bologna, 40136, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.